New product introductions offset slightly weaker Q4 results due to COVID-19 headwinds and international pressure.

While the Trauma segment was not impacted as heavily due to COVID-19 headwinds, companies that play within the space were impacted by deferrals of elective surgeries such as limb restoration. Long bone trauma volumes remained healthy as players cited new product introductions as growth drivers for the segment. 

Among the many topics covered in detail in our comprehensive Q421/FY21 Trauma Market Recap* are:

Trauma market continues to ride the wave of healthy growth with positive returns for current players and new players start to stir the waters

Trauma players rode the wave of another quarter of healthy returns as trauma procedures were not as impacted by the rise in the Delta variant as its elective procedure counterparts. The Trauma Market closed Q3 up +4.5% YoY compared to Q320, with the US up +5.8% YoY.

Among the many topics covered in detail in our comprehensive Q321 Trauma Market Recap* are:

New product introductions and innovative technologies set the stage for AOFAS 2021.

At the American Orthopaedic Foot & Ankle Society (AOFAS) meeting in Charlotte, NC, SmartTRAK identified several key themes and takeaways from the meeting as manufacturers showcased innovation through new product introductions, continue to focus on hallux valgus corrections and the associated instrumentation allowing for reproducible outcomes and the advancements of 3D printed solutions.

The Luster of New Products Help Drive Healthy Foot & Ankle Competition

The foot & ankle space does not look like it is slowing down anytime soon based on the products highlighted at AOFAS. Innovation is helping to drive growth in the US market for Foot & Ankle Repair and Reconstruction, which is projected to reach a 5-year CAGR of +4.9% according to SmartTRAK’s Foot & Ankle Market Overview. Newsworthy highlights include:

Trauma market rebounds as top segments drive growth amid easy YoY comps

The Trauma Market experienced another quarter of healthy growth as the WW and US Trauma Markets ended Q221 up YoY compared to Q220.  Looking forward to Q321, SmartTRAK feels that trauma procedures will likely not be as heavily impacted by the rise in the Delta variant as its elective procedure counterparts. We will continue to monitor the situation as the variant impacts states, as recently observed in Texas.

Among the many topics covered in detail in our comprehensive Q221 Trauma Market Recap* are:

Inclement weather, strong product performances and the impact of M&A all help to drive another quarter of healthy growth for the Trauma Market.

The Trauma Market experienced the third sequential quarter of increasingly healthy growth as both the WW and US Trauma Markets were up YoY. New product introductions, along with inclement weather in the US and EU drove trauma procedures during the first quarter of 2021.

During the Stryker Q121 earnings call, management noted that their trauma business, which is less elective in nature, benefited from inclement weather in the US and Europe in February. 

Among the many topics covered in detail in our comprehensive Q121 Trauma Market Recap* are:

Healthy growth closes out Q420 as the trauma segment recovers in the second half of the year hitting pre-COVID levels.

Despite the rise in COVID cases during Q4, the Trauma Market fared well resulting in positive YoY revenue gains that represented healthy, pre-COVID level volumes. Trauma players cited another quarter of healthy trauma growth, as the second half of the year ended on an upswing (+5.6% vs. H219). Top US market leaders, DePuy Synthes (49.4% Q420 US share), Stryker (27.3%) and Smith & Nephew (9.8%) all reported improved sequential gains.

Among the many topics covered in the comprehensive Q420/FY20 Trauma Market Recap* are:

As companies ride the latest wave of COVID-19, SmartTRAK predicts the trends and technologies that will continue to advance the trauma industry in 2021 and 2022.

Trend #1: Procedures Return to Near-Normal Levels in 2021

After the first swell of COVID-19 this past March, elective surgeries took a major hit. As most procedures were postponed during this phase of the pandemic, the trauma segment was impacted to a lesser extent. In early 2020, trauma surgeons reported seeing definite decreases in volumes due to stay-at-home orders, with polytrauma being almost negligible in certain US cities. Geriatric fractures also decreased, but to a lesser extent according to the OTA COVID-19 Webinar discussion. Despite the decrease, surgeons treated the majority of trauma fracture fixation procedures and provided conservative treatment in only a small portion of patients who were in facilities or areas heavily impacted by COVID-19.

With restrictions lifted during Q320, the trauma segment rebounded from the prior quarter as procedural volumes increased and revenues hit pre-COVID levels.

In the absence of strict COVID restrictions, the jump ball went to the return of healthy trauma volumes during Q320. Major players cited quarterly growth in line with previous years. Q320 picked up the pace with the US Trauma Market leading the charge, up +4.6%, while the EU and ROW declined.

Among the many topics, including company revenues, shares, charts and expert analysis, covered in the comprehensive Q320 Trauma Market Recap* are:

COVID-19 halts the Trauma Market’s Q120 growth, leading to a -2.8% YoY decline globally.

Q120 was tracking as a stable quarter for the US Trauma Market, following Q419’s +3.8% growth, however, this was interrupted in mid-March by the COVID-19 pandemic. The US Trauma Market was down -1.2% YoY for the quarter, with WW revenues declining -2.8%. The non-elective trauma market experienced a reduction in trauma admissions due to the decrease in daily activities and limited driving for most of the US.

Among the many topics covered in the comprehensive Q120 Trauma Market Recap* are:

Tough comps and pricing pressure dampen growth during Q419

According to BioMedGPS’ SmartTRAK Financial Dashboard, the WW Trauma Market posted +2.8% growth, down from Q3, while the US achieved growth of +3.8%, also down from Q3. Trauma market leader DePuy Synthes (48.6% US Q4 share) reported while sales were down compared to Q319, gains were driven by overall market growth and strong adoption of their Femoral Neck System.

Tough comparisons, both YoY and sequentially, impacted the Q419 Trauma Market. The US pricing environment remains relatively steady as DePuy Synthes noted pricing pressure of -2.0%, in line with their Q2 and Q3 pricing (Q1 was -2.5%). Zimmer Biomet’s SET pricing improved in Q4 at -1.8% vs. Q3’s -2.0%. BioMedGPS believes 2019 pricing trended at -2.0 to -2.5%.

Among the many topics covered in the comprehensive Q419/FY19 Trauma Market Recap* are: